Abbott India

Why is Abbott India Ltd. falling/rising?

As of 23-Jun, Abbott India Ltd. is facing a decline in its stock price, currently at Rs 25,574.00, down 1.92%. The stock has underperformed its sector and is trading below its moving averages, indicating a bearish trend amid decreasing investor participation and high valuation metrics.

As of 23-Jun, Abbott India Ltd. is experiencing a decline in its stock price, currently at Rs 25,574.00, which reflects a decrease of Rs 500.5 or 1.92%. This downward trend is evident from several factors. Over the past week, the stock has fallen by 1.97%, and it has underperformed the sector by 2.38% today. Additionally, the stock has been on a consecutive decline for the last two days, accumulating a total drop of 2.18% during this period.<BR><BR>The stock is also close to its 52-week low, being only 1.89% away from Rs 25,164. The performance metrics indicate that Abbott India is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 9.03% compared to the 5-day average.<BR><BR>Despite the company's high management efficiency and being net-debt free, the stock's valuation appears expensive, with a Price to Book Value of 11.4, and it has underperformed against its peers historically. The stock's return of -17.64% over the past year, despite a 9.7% increase in profits, suggests that the market sentiment is not favorable, as indicated by a high PEG ratio of 3.6. Overall, the combination of poor short-term performance, declining investor interest, and high valuation metrics contributes to the stock's current downward trajectory.

Which are the latest news on Abbott India?

How big is Abbott India?

As of 10th June, Abbott India Ltd. has a market capitalization of 56,130.00 Cr, with recent net sales of 6,929.05 Cr and a net profit of 1,552.02 Cr.

As of 10th June, Abbott India Ltd. has a market capitalization of 56,130.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Abbott India reported Net Sales of 6,929.05 Cr and a Net Profit of 1,552.02 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 4,233.15 Cr and Total Assets of 5,902.35 Cr.

Who are in the management team of Abbott India?

The management team of Abbott India includes Chairman Munir Shaikh, Managing Director Vivek Vasudev Kamath, and several Non-Executive and Independent Directors such as Kaiyomarz Marfatia, Ambati Venu, Anisha Motwani, Sudarshan Jain, Shalini Kamath, and Sabina Ewing. They are responsible for guiding the company's strategic direction and governance.

The management team of Abbott India includes the following members:<BR><BR>1. **Munir Shaikh** - Chairman (Non-Executive)<BR>2. **Kaiyomarz Marfatia** - Non-Executive Director<BR>3. **Ambati Venu** - Non-Executive Director<BR>4. **Anisha Motwani** - Independent Director<BR>5. **Sudarshan Jain** - Independent Director<BR>6. **Shalini Kamath** - Independent Director<BR>7. **Sabina Ewing** - Non-Executive Director<BR>8. **Vivek Vasudev Kamath** - Managing Director<BR>9. **Mahadeo Karnik** - Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance. If you need more specific information about any of the members or their roles, feel free to ask!

Who are the peers of the Abbott India?

Abbott India's peers include Aurobindo Pharma, Laurus Labs, Biocon, Alkem Lab, Glenmark Pharma, Anthem Bioscienc, Ipca Labs, Gland Pharma, and Ajanta Pharma. Abbott India has average growth and management risk, with a 1-year return of -16.67%, while Laurus Labs leads with a 1-year return of 106.62%.

Peers: The peers of Abbott India are Aurobindo Pharma, Laurus Labs, Biocon, Alkem Lab, Glenmark Pharma, Anthem Bioscienc, Ipca Labs, Gland Pharma, and Ajanta Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Alkem Lab, and Ajanta Pharma, while Good management risk is found at Laurus Labs, Glenmark Pharma, Anthem Bioscienc, Ipca Labs, and Gland Pharma, and Average management risk is noted at Aurobindo Pharma and Biocon. Below Average growth is seen at Aurobindo Pharma, Laurus Labs, Biocon, Alkem Lab, Gland Pharma, and Ajanta Pharma, while Average growth is observed at Abbott India and Glenmark Pharma, and Excellent growth is noted at Anthem Bioscienc. Excellent capital structure is present at Aurobindo Pharma, Alkem Lab, Abbott India, Anthem Bioscienc, Ipca Labs, Gland Pharma, and Ajanta Pharma, while Average capital structure is found at Laurus Labs, and Good capital structure is noted at Glenmark Pharma.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 106.62%, while Abbott India has the lowest at -16.67%. Abbott India's 1-year return is significantly lower than that of Laurus Labs. Additionally, Aurobindo Pharma, Alkem Lab, Glenmark Pharma, and Glaxosmi. Pharma all have negative six-month returns.

What does Abbott India do?

Abbott India Ltd. is a leading multinational pharmaceutical company in the mid-cap market, reporting net sales of ₹1,710 Cr and a net profit of ₹395 Cr for Q1 2026. Key metrics include a P/E ratio of 36.00, a dividend yield of 1.82%, and a market cap of ₹56,130 Cr.

Overview: <BR>Abbott India Ltd. is a leading multinational pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry within the mid-cap market segment.<BR><BR>History: <BR>Abbott India Ltd. was incorporated in an unspecified year and has maintained its status as a prominent player in the pharmaceutical sector. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,710 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 395 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 56,130 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.82% <BR>Debt Equity: -0.44 <BR>Return on Equity: 32.51% <BR>Price to Book: 11.65<BR><BR>Contact Details: <BR>Address: Unit No 3 Corporate Park, Sion Trombay Road Chembur Mumbai Maharashtra : 400071 <BR>Tel: 91-22-67978888/50461000/2000/1119 <BR>Email: investorrelations.india@abbott.com <BR>Website: http://www.abbott.co.in

Should I buy, sell or hold Abbott India Ltd.?

Are Abbott India Ltd. latest results good or bad?

Abbott India Ltd.'s latest Q4 FY26 results are mixed; while net profit rose by 7.60% and net sales grew by 6.54%, there was a sequential decline in sales of 0.84%, raising concerns about future demand and growth sustainability. Investors should consider both the strong profitability and the challenges in revenue growth.

Abbott India Ltd.'s latest results for Q4 FY26 can be considered mixed, with some positive aspects but also areas of concern. <BR><BR>On the positive side, the company reported a net profit of ₹394.93 crore, which reflects a year-on-year increase of 7.60%. Additionally, net sales reached ₹1,709.51 crore, marking a 6.54% growth compared to the same quarter last year. The operating margin improved to 28.13%, up 142 basis points from the previous year, indicating effective cost management and pricing power.<BR><BR>However, there are notable challenges as well. The sequential decline in net sales of 0.84% from the previous quarter suggests potential headwinds in demand momentum. This decline is concerning, especially as the pharmaceutical sector typically sees seasonal growth in the final quarter. Furthermore, while the full fiscal year FY26 showed an overall sales increase of 8.11%, the growth rate still lags behind broader sector averages.<BR><BR>In summary, while Abbott India demonstrates strong profitability and margin expansion, the modest revenue growth and recent sequential decline raise questions about future demand and growth sustainability. Investors may need to weigh these factors carefully when assessing the company's performance.

Is Abbott India technically bullish or bearish?

As of December 2, 2025, the technical trend has shifted to a bearish stance, driven by bearish indicators like the weekly MACD and Bollinger Bands, despite some bullish momentum in the weekly RSI.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include the weekly MACD and Bollinger Bands both indicating bearish conditions, alongside bearish moving averages on the daily timeframe. Although the weekly RSI shows bullish momentum, it is overshadowed by the overall bearish signals from other indicators. The Dow Theory presents a mildly bullish view on the weekly chart, but this is not enough to counter the prevailing bearish trend.

How has been the historical performance of Abbott India?

Abbott India has shown consistent growth from March 2020 to March 2025, with net sales increasing from 4,093.14 crore to 6,409.15 crore, and profit after tax rising from 592.93 crore to 1,414.44 crore. Key financial metrics, including operating profit and earnings per share, have also significantly improved during this period.

Answer:<BR>Abbott India's historical performance shows a consistent growth trend in net sales, operating profit, and profit after tax over the past several years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Abbott India has demonstrated strong growth in net sales, increasing from 4,093.14 crore in March 2020 to 6,409.15 crore in March 2025. The total operating income followed a similar upward trajectory, reaching 6,409.15 crore in March 2025, up from 4,093.14 crore in March 2020. Operating profit (PBDIT) also saw significant growth, rising from 870.84 crore in March 2020 to 1,970.18 crore in March 2025. Profit before tax increased from 802.70 crore in March 2020 to 1,886.95 crore in March 2025, while profit after tax rose from 592.93 crore to 1,414.44 crore during the same period. The company's earnings per share (EPS) improved markedly from 279.03 in March 2020 to 665.62 in March 2025. Total assets grew from 3,532.41 crore in March 2020 to 5,902.35 crore in March 2025, reflecting a robust balance sheet. Cash flow from operating activities increased from 626.00 crore in March 2020 to 1,011.00 crore in March 2025, indicating strong operational efficiency. Overall, Abbott India has shown a solid financial performance with consistent growth across key metrics over the years.

Who are the top shareholders of the Abbott India?

The top shareholder of Abbott India is Abbott Capital India Limited, holding 50.44%. Other significant shareholders include mutual funds with 7.77%, SBI Large & Midcap Fund at 2.66%, and individual investors with a combined 13.35%.

The top shareholders of Abbott India include Abbott Capital India Limited, which holds the largest stake at 50.44%. The company also has a diverse range of shareholders, including mutual funds, with 35 schemes collectively holding 7.77%. Additionally, there are 12 foreign institutional investors (FIIs) that hold 0.16% of the shares. The highest public shareholder is the SBI Large & Midcap Fund, which owns 2.66%. Individual investors collectively hold 13.35% of the company's shares.

Is Abbott India overvalued or undervalued?

As of October 27, 2022, Abbott India is considered very expensive with a PE ratio of 47.32 and other high valuation metrics, indicating it is overvalued compared to peers like Sun Pharma and Cipla, despite its recent strong performance against the Sensex.

As of 27 October 2022, Abbott India's valuation grade moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently overvalued, with a PE ratio of 47.32, a Price to Book Value of 19.01, and an EV to EBITDA of 38.88. These ratios suggest that investors are paying a premium for the stock compared to its earnings and book value.<BR><BR>In comparison to its peers, Abbott India's valuation stands out as particularly high; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla is valued more attractively with a PE of 22.99. Additionally, Abbott's PEG ratio of 2.67 further emphasizes its overvaluation relative to peers like Divi's Lab, which has a PEG of 2.15. Despite outperforming the Sensex over various periods, including a 16% return over the past year compared to the Sensex's 7.63%, the current valuation metrics suggest that investors may be overestimating Abbott India's growth potential.

When is the next results date for Abbott India?

No Upcoming Board Meetings

Has Abbott India declared dividend?

Yes, Abbott India Ltd. has declared a dividend of 410% (₹410 per share) with an ex-date of July 19, 2024, resulting in a dividend yield of 1.3%. The company has shown strong total returns over various periods, with a total return of 104.28% over the last 4 years.

Abbott India Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 4100%<BR>- Amount per share: 410 per share<BR>- Ex-date: 19 Jul 24<BR><BR>Dividend Yield: 1.3%<BR><BR>Total Returns by Period:<BR>In the last 6 months, Abbott India experienced a price return of 9.35% with no dividend return, resulting in a total return of 9.35%.<BR><BR>Over the past year, the company achieved a price return of 17.76% and a dividend return of 1.46%, leading to a total return of 19.22%.<BR><BR>In the 2-year period, Abbott India saw a price return of 45.62% and a dividend return of 2.56%, culminating in a total return of 48.18%.<BR><BR>For the 3-year period, the price return was 79.7% with a dividend return of 4.01%, resulting in a total return of 83.71%.<BR><BR>In the last 4 years, the company recorded a price return of 99.09% and a dividend return of 5.19%, achieving a total return of 104.28%.<BR><BR>Over the 5-year period, Abbott India had a price return of 86.07% and a dividend return of 6.21%, leading to a total return of 92.28%.<BR><BR>Overall, Abbott India has declared a substantial dividend, and the total returns across various periods indicate strong performance, particularly in price appreciation. The combination of high dividend yield and significant total returns reflects positively on the company's financial health.